Goodyear Tire & Rubber Co vs Moderna, Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $6.11 (market cap $1.75B), while Moderna, Inc. trades at $63.69 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 13.8× Goodyear Tire & Rubber Co's market cap, and Moderna, Inc. is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| GT | MRNA | |
|---|---|---|
Market Cap | $1.75B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $81.80 |
52-Week Low | $5.58 | $22.36 |
Enterprise Value | $9.11B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $5.98, down 0.83% on the day, reflecting ongoing pressure from declining revenue and a significant net loss of $1.72 billion in 2025. Technical indicators are bearish, with moving averages signaling a downtrend, while fundamentals show a low P/E of 4.69 and P/B of 0.62, suggesting potential undervaluation despite negative profitability metrics like a -14.37% net income margin. Recent Q2 2026 earnings showed a loss of $0.61 per share, beating expectations but highlighting volume challenges.
GT presents a high-risk opportunity with its cheap valuation offset by weak earnings and cash flow volatility. Analyst sentiment is mixed, with 34.62% buy ratings, but risks include persistent volume declines, high debt, and competitive pressures. The stock's outlook hinges on operational improvements and market stabilization, making it speculative for value investors.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Trailing returns across standard periods
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →